Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children
1 other identifier
interventional
594
2 countries
2
Brief Summary
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI vaccines in African children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started May 2022
Typical duration for phase_1
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 9, 2021
CompletedFirst Posted
Study publicly available on registry
December 13, 2021
CompletedStudy Start
First participant enrolled
May 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 27, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 27, 2025
CompletedApril 8, 2026
September 1, 2025
3 years
December 9, 2021
April 7, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Safety
Solicited adverse events: * Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination. * Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination. Unsolicited adverse events * Occurrence of unsolicited adverse events for 28 days following the vaccination. Laboratory adverse events * Change from baseline for safety laboratory measures thought to be clinically significant. Serious adverse events • Occurrence of serious adverse events for the whole study duration.
2 years
Immunogenicity
* To assess the humoral immunogenicity of R21/Matrix-M as a single- vial formulation in 5-36-month-old African children, compared with the two-vial formulation, 0, 30, 180 and 365 days after the administration of the third dose of R21/Matrix-M; and 0, 30, 180 and 365 days after the administration of a booster dose. * To assess the humoral immunogenicity of EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, when given with and without R21/Matrix-M, 0, 30, 180 and 360 days after the administration of the third dose of R21/Matrix-M * To assess the humoral immunogenicity of EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccines, given as part of EPI at 6, 10 and 14 weeks of age, when given with and without R21/Matrix-M, 0, 30, 180 and 360 days after the administration of the third dose of R21/Matrix-M or the EPI vaccines.
2 years
Secondary Outcomes (2)
Safety of a delayed third dose
2 years
Immunogenicity of a delayed third dose
2 years
Study Arms (9)
Groups 1a, 2a and 3a
EXPERIMENTAL60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
Group 1b, 2b and 3b
EXPERIMENTAL60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
Group 4a
EXPERIMENTAL150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
Group 4b
ACTIVE COMPARATOR150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
Group 4c
EXPERIMENTALGroup 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
Group 5a
EXPERIMENTAL30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
Group 5b
ACTIVE COMPARATOR30 children who will receive 3 doses of pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
Group 6a
EXPERIMENTAL30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
Group 6b
EXPERIMENTAL30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
Interventions
Adjuvanted malaria vaccine in a single vial formulation
Adjuvanted malaria vaccine in a double vial formulation
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine part of the EPI vaccination schedule
Eligibility Criteria
You may qualify if:
- Age:
- Group 1: The child is 5-11 months of age at the time of randomization (i.e. up to the day before of their first birthday).
- Group 2: The child is 12-23 months of age at the time of randomization (i.e. up to the day before of their second birthday).
- Group 3: The child is 24-36 months of age at the time of randomization (i.e. up to the day of their third birthday).
- Group 4: The child is 6-7 months of age at the time of randomization.
- Group 5: The child is 6 weeks of age at the time of randomization and have not received any dose of the pentavalent vaccine, pneumococcal vaccine, rotavirus vaccine, IPV and only the first dose of the OPV.
- Group 6: The child is aged 5-36 months at the time of their first vaccination
- Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial.
- The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study.
- The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial.
You may not qualify if:
- The child has previously received a malaria vaccine.
- The child is enrolled in another malaria intervention trial that could interfere with the results of this study.
- The child has a history of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.
- The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunisations.
- The child has major congenital defects.
- The child has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of ≤7.4 g/dL.
- The child has had a blood transfusion within one month of enrolment.
- The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- The child has malnutrition requiring hospital admission.
- The child has an acute or chronic, clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV or asplenia.
- The child has received an investigational drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- The child is currently participating in another clinical trial if likely to affect data interpretation of this trial
- The child has any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Clinically significant laboratory abnormality as judged by the study clinician
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako
Bamako, Mali
CCVTM, University of Oxford
Oxford, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adrian Hill
University of Oxford
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- For groups 1, 2 and 3, participants and investigators will be blinded to group allocation. Study staff involved in storage and preparation of the vaccine will be aware of vaccine assignment but these staff will play no other role in the study. The Sponsor team will remain blinded with the exception of designated members of the laboratory team that will perform the final evaluation of the data. For groups 4 and 5, no study staff or participants will be blinded as the number of vaccinations in each group is different. For group 6, no study staff or participants will be blinded as the schedule of vaccinations in each group is different.
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 9, 2021
First Posted
December 13, 2021
Study Start
May 14, 2022
Primary Completion
May 27, 2025
Study Completion
May 27, 2025
Last Updated
April 8, 2026
Record last verified: 2025-09